A combination of anti-PD-1 and anti-CTLA-4 therapies produced an enhanced ability to control EBV infection, leading to reductions in lymphomas, increased EBV effector responses, and decreases in EBV-infected B cells [150]. The gene discussed is CTLA4; the disease is Epstein-Barr virus infection.